CAR-T or Chimeric Antigen Receptor T cells are a sub component of Adoptive T Cell therapy (ACT) , a promising new treatment intervention for cancer.
In ACT, a patient’s individual T cells are removed and manipulated so they have an increased capacity to fight cancer. The therapy is usually personalized (autologous) for a specific patient.
Chimeric antigen receptor T cells present hybrid receptors consisting of an antigen binding domain of an antibody (e.g. directed to CD19) fused to the T-cell receptor signalling domain. So far, the technology has undergone four generations of development, where second-generation approaches have shown remarkable responses in clinical studies. Complete remission in up to 90% of patients have been reported for relapsed or refractory B-cell Acute Lymphoblastic Leukaemia (B-ALL). Since 2015/2016 commercial interest
has heightened in the development of CAR-T therapies with companies such as Novartis, Pfizer (Cellectis), Medimmune, Juno Therapeutics, and Kite Pharma involved in clinical studies, mainly against hematological cancers.
This MarketVIEW product consists of a product consists of a detailed Executive presentation (~91 slides) and MS-Excel work book summarizing latest developments in
CAR-T therapies with a full review of the field to date. A searchable database of nearly 200 CAR trials has been compiled with analysis by start date, current phase, indication and sponsor type (industry and/or academic).
For the hematological cancers, detailed case studies are provided looking at clinical trial parameters and data presented to date. Future perspectives, key risks, and challenges along with summary and conclusions are provided.
This analysis is ideal for those wishing to gain an up-to-date understanding of the CAR-T landscape.
THIS PRODUCT IS A SUMMARY PRESENTATION + ONE WORKBOOK